MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
18 déc. 2024 07h00 HE
|
MannKind
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
16 déc. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
11 déc. 2024 06h00 HE
|
MannKind
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
07 nov. 2024 16h02 HE
|
MannKind
MANNKIND CORPORATION REPORTS
2024 THIRD QUARTER FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE
MannKind to Present at 2024 UBS Healthcare Conference
05 nov. 2024 16h15 HE
|
MannKind
MannKind to Present at 2024 UBS Healthcare Conference
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
04 nov. 2024 06h05 HE
|
MannKind
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
31 oct. 2024 16h05 HE
|
MannKind
Mannkind Corporation to Hold 2024 Third Quarter
Financial Results Conference Call on November 7, 2024
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
30 oct. 2024 21h00 HE
|
MannKind
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
30 sept. 2024 06h00 HE
|
MannKind
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS
OR AUTOMATED PUMPS TO INHALED INSULIN
マンカインド (MannKind) 、非結核性抗酸菌症（NTM）肺疾患治療用クロファジミン (Clofazimine) 吸入懸濁液の日本における第 3 相臨床試験（ICoN-1）開始に向けたPMDA承認取得を発表
18 sept. 2024 06h15 HE
|
MannKind
韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- 内分泌疾患および希少肺疾患患者を対象とした革新的な吸入治療薬および機器の開発・商業化に取り組んでいる マンカインド・コーポレーション (MannKind Corporation)...